Strategic acquisition strengthens manufacturing footprint, accelerates innovation, and supports rising global demand for emissions solutions.
Charles River Laboratories will pay $60 million for the remaining shares of PathoQuest and $510 million for acquiring K.F.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback